COG NCTN Network Group Operations Center - Year 10 Administrative Supplements
COG NCTN 网络集团运营中心 - 10 年级行政补充资料
基本信息
- 批准号:10888036
- 负责人:
- 金额:$ 354.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-21 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:1 year oldAccelerationAcuteAcute Myelocytic LeukemiaAdministrative SupplementAdolescentAustraliaBrain Stem GliomaCanadaCancer CenterCancer PatientCaringCause of DeathCell TherapyChildChild SupportChildhoodChildhood LeukemiaClinicalClinical ResearchClinical TrialsClinical Trials DesignCollaborationsCollectionCommunitiesComplicationCountryDevelopmentDiagnosisDiseaseDoseEligibility DeterminationEnrollmentEnsureFamilyFoundationsFunctional disorderGenerationsGoalsHormonalImmunotherapyInfrastructureInstitutionInterdisciplinary StudyKnowledgeLaboratoriesLate EffectsLeadMalignant Childhood NeoplasmMalignant NeoplasmsMethodsMissionMolecularMorbidity - disease rateNational Cancer InstituteNational Clinical Trials NetworkNeuroblastomaNew ZealandOrganOutcomePatientsPediatric HospitalsPediatric Oncology GroupPharmaceutical PreparationsPopulation HeterogeneityPopulation ResearchPositioning AttributeProductivityPrognosisQuality of lifeRare DiseasesResearchResearch PersonnelScientistSecond Primary CancersSiteSurvival RateSurvivorsTissuesTranslational ResearchUnited StatesUniversitiesWorkanticancer researchcancer diagnosiscancer therapychemotherapychildhood cancer survivorclinical translationdesignexperiencehealth related quality of lifehigh riskimprovedimproved outcomeinnovationmembermultidisciplinarynovel therapeutic interventionoperationorganizational structurereproductivesmall moleculesuccesssurvivorshiptranslational study
项目摘要
PROJECT SUMMARY
Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the
prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood cancers,
many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number of childhood
cancers, however, has been limited, with approximately 50% of children with acute myelogenous leukemia, 50%
of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing
to their disease. In the US, cancer remains the leading cause of death from disease in children greater than one
year of age. Moreover, the late effects of cancer treatment, including permanent organ and tissue damage,
hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the
500,000 survivors of childhood cancer (estimated as of 2020) experiencing a significant health related quality of
life complication from childhood cancer and its treatment. Thus, despite our advances, development of new
therapeutic approaches must be a priority for childhood cancer basic, translational and clinical researchers. The
Children’s Oncology Group (COG), the world’s largest organization devoted exclusively to childhood and
adolescent cancer research, was founded 20 years ago. The COG’s multidisciplinary research team, comprised
of more than 9,000 members, conducts research at more than 220 leading children’s hospitals, universities, and
cancer centers. This proposal is for COG, as part of the National Cancer Institute’s (NCI) National Clinical Trials
Network (NCTN), to continue its collaborative research work that supports the mission of improving the outcome
for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer
that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest
potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases,
we will study novel therapeutic approaches including but not limited to targeted small molecule drugs,
immunotherapies and cellular therapies. The COG research portfolio importantly also includes clinical trials
focused on improving the quality of life for children with cancer and childhood cancer survivors. As more than
90% of children diagnosed with cancer in the US are treated at COG member institutions, COG has the ability
to offer a diverse population of children with cancer and their families the opportunity to participate in innovative
research. This research effort includes allowing for collection and annotation of biospecimens from all children
with cancer, providing the foundation for discovery and accelerating the most promising research efforts
conducted in laboratories around the world. The proposal is for support of the COG Network Operations Center,
clinician-scientists who develop and conduct research, and for member sites to participate through enrollment of
eligible subjects.
项目摘要
自从60多年前引入化疗治疗儿童白血病以来,
儿童癌症的预后已显著改善。儿童癌症的总体5年生存率,
其中许多在化疗前是致命的,现在是84%。一些儿童的进步
然而,癌症的治疗是有限的,大约50%的儿童患有急性骨髓性白血病,50%
的高危神经母细胞瘤儿童,以及超过90%的脑干胶质瘤儿童,
他们的疾病。在美国,癌症仍然是一岁以上儿童疾病死亡的主要原因。
年龄。此外,癌症治疗的晚期效应,包括永久性器官和组织损伤,
荷尔蒙和生殖功能障碍以及第二种癌症,特别令人关注,
500,000名儿童癌症幸存者(估计截至2020年)经历了显著的健康相关质量,
儿童癌症的生活并发症及其治疗因此,尽管我们的进步,新的发展,
治疗方法必须是儿童癌症基础、转化和临床研究人员的优先事项。的
儿童肿瘤学小组(COG)是世界上最大的专门致力于儿童和
青少年癌症研究中心成立于20年前。COG的多学科研究团队,包括
该组织拥有9,000多名成员,在220多家领先的儿童医院、大学和
癌症中心该提案是针对COG的,作为国家癌症研究所(NCI)国家临床试验的一部分
网络(NCTN),继续其合作研究工作,支持改善成果的使命
为所有患有癌症的儿童提供帮助。COG将为癌症儿童设计和开展临床转化研究
该研究建立在对儿科恶性肿瘤分子基础的日益了解的基础上,
改善结果的潜力。采用适合罕见病研究的创新临床试验设计,
我们将研究新的治疗方法,包括但不限于靶向小分子药物,
免疫疗法和细胞疗法。重要的是,COG的研究组合还包括临床试验
重点是提高癌症儿童和儿童癌症幸存者的生活质量。余
在美国,90%被诊断患有癌症的儿童在COG成员机构接受治疗,COG有能力
为不同的癌症儿童及其家人提供参与创新的
research.这项研究工作包括允许收集和注释所有儿童的生物标本
与癌症,提供基础的发现和加速最有前途的研究工作
在世界各地的实验室进行。该提案是为了支持COG网络运营中心,
开发和开展研究的临床医生-科学家,成员研究中心通过招募
合格受试者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Douglas S. Hawkins其他文献
Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.
用于高危神经母细胞瘤、高级别胶质瘤和难治性/复发性儿童实体瘤的 I 期拓扑替康准备方案。
- DOI:
- 发表时间:
2000 - 期刊:
- 影响因子:0
- 作者:
Julie R. Park;Julie R. Park;Julie R. Park;John T. Slattery;T. Gooley;Douglas S. Hawkins;Douglas S. Hawkins;Karen L. Lindsley;J. Villablanca;K. Matthay;Jean E. Sanders;Jean E. Sanders - 通讯作者:
Jean E. Sanders
Investigating the heterogeneity of alkylating agents’ efficacy and toxicity between sexes: A systematic review and meta‐analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)
调查烷化剂在性别之间的功效和毒性的异质性:比较环磷酰胺和异环磷酰胺的随机试验的系统回顾和荟萃分析(MAIAGE 研究)
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:3.2
- 作者:
B. Fresneau;Allan Hackshaw;Douglas S. Hawkins;M. Paulussen;James R. Anderson;I. Judson;S. Litière;U. Dirksen;Ian J. Lewis;H. M. V. D. Berg;Natalie Gaspar;H. Gelderblom;Jeremy Whelan;Alan V. Boddy;Keith Wheatley;J. Pignon;F. Vathaire;M. C. L. Deley;G. Teuff - 通讯作者:
G. Teuff
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe
临床试验中横纹肌肉瘤的分子检测以改善风险分层和预后:来自欧洲儿科软组织肉瘤研究组、儿童肿瘤组和合作性软组织肉瘤研究组的共识观点
- DOI:
10.1016/j.ejca.2022.05.036 - 发表时间:
2022-09-01 - 期刊:
- 影响因子:7.100
- 作者:
Simone Hettmer;Corinne M. Linardic;Anna Kelsey;Erin R. Rudzinski;Christian Vokuhl;Joanna Selfe;Olivia Ruhen;Jack F. Shern;Javed Khan;Alexander R. Kovach;Philip J. Lupo;Susanne A. Gatz;Beat W. Schäfer;Samuel Volchenboum;Véronique Minard-Colin;Ewa Koscielniak;Douglas S. Hawkins;Gianni Bisogno;Monika Sparber-Sauer;Rajkumar Venkatramani;Janet Shipley - 通讯作者:
Janet Shipley
Alternative mRNA splicing in anthracycline-induced cardiomyopathy – a COG-ALTE03N1 report
- DOI:
10.1186/s40959-025-00345-2 - 发表时间:
2025-05-17 - 期刊:
- 影响因子:3.200
- 作者:
Purnima Singh;David K. Crossman;Changde Cheng;Patrick J. Trainor;Noha Sharafeldin;Xuexia Wang;Liting Zhou;Lindsey Hageman;Saro H. Armenian;Frank M. Balis;Douglas S. Hawkins;Frank G. Keller;Melissa M. Hudson;Joseph P. Neglia;Jill P. Ginsberg;Wendy Landier;Smita Bhatia - 通讯作者:
Smita Bhatia
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma
横纹肌肉瘤儿童的种系基因检测和生存结果
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:13.8
- 作者:
Bailey A Martin;He Li;Michael E Scheurer;Dana L Casey;Shannon Dugan;Deborah A Marquez;D. Muzny;Richard A. Gibbs;D. Barkauskas;David Hall;Douglas R Stewart;J. Schiffman;Matthew T McEvoy;Javed Khan;D. Malkin;C. Linardic;B. Crompton;J. Shern;S. Skapek;R. Venkatramani;Douglas S. Hawkins;A. Sabo;Sharon E. Plon;Philip J. Lupo - 通讯作者:
Philip J. Lupo
Douglas S. Hawkins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Douglas S. Hawkins', 18)}}的其他基金
COG NCTN Network Group Operations Center - Year 10 STAR Act COG) Outcomes & Survivorship (LTE) Committee
COG NCTN 网络集团运营中心 - 第 10 年 STAR 法案 COG) 结果
- 批准号:
10918928 - 财政年份:2023
- 资助金额:
$ 354.19万 - 项目类别:
COG NCTN Network Group Operations Center - Year 9 Supplement
COG NCTN 网络集团运营中心 - 9 年级补充材料
- 批准号:
10665291 - 财政年份:2022
- 资助金额:
$ 354.19万 - 项目类别:
COG NCTN Year 9 BIQSFP Supplement & Progress Report
COG NCTN 9 年级 BIQSFP 补充材料
- 批准号:
10544689 - 财政年份:2014
- 资助金额:
$ 354.19万 - 项目类别:
相似海外基金
EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
- 批准号:
NE/Y000080/1 - 财政年份:2024
- 资助金额:
$ 354.19万 - 项目类别:
Research Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328975 - 财政年份:2024
- 资助金额:
$ 354.19万 - 项目类别:
Continuing Grant
SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
- 批准号:
2400967 - 财政年份:2024
- 资助金额:
$ 354.19万 - 项目类别:
Standard Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
- 批准号:
10112700 - 财政年份:2024
- 资助金额:
$ 354.19万 - 项目类别:
Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328973 - 财政年份:2024
- 资助金额:
$ 354.19万 - 项目类别:
Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328972 - 财政年份:2024
- 资助金额:
$ 354.19万 - 项目类别:
Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328974 - 财政年份:2024
- 资助金额:
$ 354.19万 - 项目类别:
Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332916 - 财政年份:2024
- 资助金额:
$ 354.19万 - 项目类别:
Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332917 - 财政年份:2024
- 资助金额:
$ 354.19万 - 项目类别:
Standard Grant
Study of the Particle Acceleration and Transport in PWN through X-ray Spectro-polarimetry and GeV Gamma-ray Observtions
通过 X 射线光谱偏振法和 GeV 伽马射线观测研究 PWN 中的粒子加速和输运
- 批准号:
23H01186 - 财政年份:2023
- 资助金额:
$ 354.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)